| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MCART2 |
| Uniprot No | Q3SY17 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-297aa |
| 活性数据 | MIDSEAHEKRPPILTSSKQDISPHITNVGEMKHYLCGCCAAFNNVAITYPIQKVLFRQQLYGIKTRDAVLQLRRDGFRNLYRGILPPLMQKTTTLALMFGLYEDLSCLLRKHVRAPEFATHGVAAVLAGTAEAIFTPLERVQTLLQNHKHHDKFTNTYQAFKALKCHGIGEYYRGLVPILFRNGLSNVLFFGLRGPIKEHLPTATTHSAHLVNDFIGGGLLGAMLGFLCFPINVVKTRIQSQIGGEFQSFPKVFQKIWLERDRKLINLFRGAHLNYHRSLISWGIINATYEFLLKFI |
| 分子量 | 60.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MCART2蛋白的假设性参考文献示例(基于公开研究模式的合理推测，实际文献可能需要进一步验证)：
---
1. **文献名称**：*Mitochondrial Carrier MCART2/SLC25A51 Facilitates NAD⁺ Transport and Regulates Cellular Metabolism*
**作者**：Smith J, Lee K, et al.
**摘要**：本研究成功表达并纯化了重组人MCART2蛋白，证实其作为线粒体NAD⁺转运体的功能。实验表明MCART2通过调控细胞内NAD⁺水平影响能量代谢和氧化应激反应，为代谢疾病治疗提供新靶点。
2. **文献名称**：*Structural Insights into the MCART2 Protein: Implications for Substrate Recognition*
**作者**：Zhang Y, Wang H, et al.
**摘要**：通过X射线晶体学解析重组人MCART2蛋白的三维结构，揭示其底物结合位点的关键氨基酸残基。该结构为理解其转运机制及设计靶向药物奠定了基础。
3. **文献名称**：*MCART2 Dysregulation in Cancer: Role of Recombinant Protein in Apoptosis Studies*
**作者**：Brown R, Garcia M, et al.
**摘要**：利用重组MCART2蛋白进行体外实验，发现其在癌细胞中表达下调会导致线粒体功能障碍并抑制凋亡，提示MCART2可能作为肿瘤治疗中的潜在生物标志物。
---
**注意**：以上文献及摘要均为示例，实际研究中可能需结合具体数据库(如PubMed、Web of Science)检索真实发表的文章。MCART2研究相对较少，建议扩展检索其可能归属的基因家族(如SLC25A)或功能关键词(如线粒体转运蛋白)。
Recombinant human MCART2 (mitochondrial carrier triple repeat 2) protein, also known as SLC25A51. is a key player in cellular metabolism due to its role as a mitochondrial NAD+ transporter. MCART2 is encoded by the SLC25A51 gene located on human chromosome 9 (9q34.11). As a member of the solute carrier family 25. it facilitates the transport of NAD+ across the mitochondrial inner membrane, a critical process for maintaining mitochondrial NAD+ pools essential for energy production (via ATP synthesis) and redox balance. Dysregulation of NAD+ metabolism is linked to aging, neurodegenerative disorders, and metabolic diseases, highlighting MCART2's physiological significance.
The recombinant form of MCART2 is typically produced using expression systems like E. coli or mammalian cells, often fused with tags (e.g., His-tag) for purification and detection. Its recombinant expression enables functional studies, including enzymatic activity assays, protein interaction mapping, and structural analysis (e.g., crystallography or cryo-EM) to elucidate transport mechanisms. Recent studies suggest MCART2’s potential as a therapeutic target, as modulating mitochondrial NAD+ levels could influence cellular resilience in conditions like cancer or mitochondrial disorders. However, its precise regulatory pathways and disease associations remain under investigation, necessitating further research using recombinant protein tools to unravel its molecular interactions and therapeutic applications.
×
